Previous 10 | Next 10 |
2023-09-27 14:47:10 ET More on Allakos Scratching The Surface: Allakos' Novel Take On Urticaria Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Financial information for Allakos For further details see: Allokos ...
2023-09-27 12:10:16 ET Shares of clinical-stage biotech company Allakos (NASDAQ: ALLK) were up more than 15% as of 11:40 a.m. on Wednesday. The stock got a boost when an analyst initiated coverage. Despite the rise, Allakos' stock is still down more than 70% so far this year. Al...
2023-09-27 09:59:57 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...
2023-09-27 08:30:53 ET MillerKnoll ( MLKN ) +17% rides 18% higher, sees improving organic orders during FQ1. Gaucho Group Holdings ( VINO ) +15% . Ginkgo Bioworks Holdings ( DNA ) +16% Announces Multi-Target RNA Discovery Collaboration w...
2023-09-18 02:07:15 ET Summary Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirentelimab's Phase 2a data is promising, particularly for omalizumab-refractory patients, but late-...
2023-09-11 17:20:07 ET Gainers: Matrix Service ( MTRX ) +10% . Adeia ( ADEA ) +7% . Allakos ( ALLK ) +5% . Nurix Therapeutics ( NRIX ) +5% . ADMA Biologics ( ADMA ) +4% . Losers: ACELYRIN ( SLRN ) ...
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced ...
2023-08-09 17:54:54 ET Allakos press release ( NASDAQ: ALLK ): Q2 GAAP EPS of -$0.41 beats by $0.08 . Allakos ended the second quarter of 2023 with $221.1 million in cash, cash equivalents and investments resulting in a net decrease in cash, cash equivalents and invest...
SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results fo...
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced ...
News, Short Squeeze, Breakout and More Instantly...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...